MindWalk Holdings Corp. (HYFT)
NASDAQ: HYFT · Real-Time Price · USD
1.630
-0.100 (-5.78%)
At close: Oct 28, 2025, 4:00 PM EDT
1.650
+0.020 (1.23%)
Pre-market: Oct 29, 2025, 7:09 AM EDT
MindWalk Holdings Revenue
MindWalk Holdings had revenue of 3.16M CAD in the quarter ending July 31, 2025, with 27.82% growth. This brings the company's revenue in the last twelve months to 25.21M, up 18.33% year-over-year. In the fiscal year ending April 30, 2025, MindWalk Holdings had annual revenue of 24.52M with 0.01% growth.
Revenue (ttm)
25.21M CAD
Revenue Growth
+18.33%
P/S Ratio
3.41
Revenue / Employee
247,137 CAD
Employees
102
Market Cap
75.23M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | 24.52M | 2.00K | 0.01% |
| Apr 30, 2024 | 24.52M | 3.85M | 18.65% |
| Apr 30, 2023 | 20.67M | 1.30M | 6.72% |
| Apr 30, 2022 | 19.36M | 1.45M | 8.11% |
| Apr 30, 2021 | 17.91M | 3.85M | 27.41% |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
HYFT News
- 7 days ago - MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy - Business Wire
- 11 days ago - MindWalk Holdings: Repositioned TechBio Platform With Early LensAI Proof Points - Seeking Alpha
- 14 days ago - MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion - Business Wire
- 19 days ago - MindWalk Holdings Corp. (HYFT) ImmunoPrecise Antibodies Ltd. - Shareholder/Analyst Call Prepared Remarks Transcript - Seeking Alpha
- 20 days ago - MindWalk Announces Share Repurchase Program - Business Wire
- 5 weeks ago - MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity - Business Wire
- 6 weeks ago - MindWalk Holdings Corp. (HYFT) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet - Business Wire